STAAR Surgical (NASDAQ:STAA – Get Free Report) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.
Other equities analysts also recently issued research reports about the stock. Stifel Nicolaus upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and upped their price objective for the company from $28.00 to $31.00 in a report on Tuesday, September 29th. Veritas Investment Research set a $31.00 target price on shares of STAAR Surgical in a research note on Tuesday, September 29th. William Blair set a $33.00 target price on shares of STAAR Surgical in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d+)” rating on shares of STAAR Surgical in a research note on Wednesday, November 11th. Finally, UBS Group set a $34.00 price target on shares of STAAR Surgical in a research note on Thursday, November 5th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $29.00.
Read Our Latest Research Report on STAA
STAAR Surgical Price Performance
Shares of STAA stock opened at $25.35 on Tuesday. The stock’s fifty day moving average price is $23.09 and its 200 day moving average price is $23.91. STAAR Surgical has a 1-year low of $15.59 and a 1-year high of $35.87. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -2,535,000.00 and a beta of 1.22.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.06. The company had revenue of $83.41 million during the quarter, compared to analysts’ expectations of $78.73 million. STAAR Surgical had a return on equity of 8.43% and a net margin of 0.16%. The firm’s revenue was down 11.9% compared to the same quarter last year. During the same period last year, the business posted $0.08 earnings per share. As a group, equities research analysts anticipate that STAAR Surgical will post 0.43 earnings per share for the current year.
STAAR Surgical declared that its Board of Directors has initiated a stock buyback program on Thursday, September 24th that allows the company to repurchase $50 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 5.2% of its shares through open market purchases. Share buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.
Institutional Investors Weigh In On STAAR Surgical
Several hedge funds have recently added to or reduced their stakes in the business. Two Seas Capital LP boosted its holdings in STAAR Surgical by 22.6% in the third quarter. Two Seas Capital LP now owns 1,304,957 shares of the medical instruments supplier’s stock valued at $29,505,000 after purchasing an additional 240,568 shares during the last quarter. Algert Global LLC purchased a new position in shares of STAAR Surgical during the 3rd quarter valued at about $24,683,000. American Capital Management Inc. purchased a new position in shares of STAAR Surgical during the 2nd quarter valued at about $24,291,000. Dimensional Fund Advisors LP lifted its holdings in shares of STAAR Surgical by 39.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 820,782 shares of the medical instruments supplier’s stock valued at $15,348,000 after buying an additional 230,582 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of STAAR Surgical in the 2nd quarter valued at about $6,578,000. 96.70% of the stock is owned by hedge funds and other institutional investors.
About STAAR Surgical
STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses. Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.
Further Reading
- Five stocks we like better than STAAR Surgical
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
